Description and assessment of a model for GSK-3β database virtual screening

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 2, 2010, Pages 152-157

  Ventimila, Nadege ^a   Dupont, Pierre Yves ^a   Laguerre, Michel ^a   Dessolin, Jean ^a  

^a CNRS   (France)

Author keywords

Docking; GSK 3 ; Scoring functions; Virtual screening

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

BIOLOGICAL ACTIVITY; COMPUTER MODEL; CONFERENCE PAPER; CONFORMATION; CRYSTAL STRUCTURE; DATA BASE; METHODOLOGY; MOLECULAR DOCKING; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; SCREENING TEST; VIRTUAL SCREENING;

ALGORITHMS; ANIMALS; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MODELS, CHEMICAL; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, QUATERNARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; USER-COMPUTER INTERFACE;

EID: 77949454502     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903169410     Document Type: Conference Paper

References (26)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042
3. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
4. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-336
5. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, et al. Structural basis for p38′ MAP kinase quinazolinone and pyridolpyrimidine inhibitor specificity. Nat Struct Biol 2003;10:764-769
6. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesityprone C57BL/6J mice. Diabetes 1999;48:1662-1666
7. Takashima A, Yamaguchi H, Noguchi K, Michel G, Ishiguro K, Sato K, et al. Amyloid β peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3 βin rat hippocampal neurons. Neurosci Lett 1995;198:83-86
8. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-384
9. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor kB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-2081.
10. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990;9:2431-2438
11. Moustakas DT, Lang PT, Pegg S, Pettersen E, Kuntz ID, Brooijmans N, et al. Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des 2006;20:601-619
12. Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, et al. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 2003;333:393-407.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242
14. http://www.accelrys.com/products/
15. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins Struct Func Gen 1988;4:31-47.
16. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003;10:1255-1266
17. Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, et al. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 2008;51:2062-2077
18. Schwartz D, ed. Méthodes Statistiques à l'Usage des Médecins et des Biologistes. Paris: Flammarion Médecine-Sciences, 1993.
19. Liu HY, Kuntz ID, Zou X. Pairwise GB/SA scoring function for structurebased drug design. J Phys Chem B 2004;108: 5453-5462
20. Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002;16:11-26.
21. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 2000;295:337-356
22. Velec HF, Gohlke H, Klebe G. DrugScore(CSD)-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J Med Chem 2005;48:6296-6303
23. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-282
24. Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol 2004;337:209-225
25. Withers IM, Mazanetz MP, Wang H, Fischer PM, Laughton CA. Active site pressurization: a new tool for structure-guided drug design and other studies of protein flexibility. J Chem Inf Model 2008;48:1448-1454
26. Alvarez JC. High-throughput docking as a source of novel drug leads. Curr Opin Chem Biol 2004;8:365-370